Phathom Pharmaceuticals Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
/ 
Frequently asked questions
To buy Phathom Pharmaceuticals Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Phathom Pharmaceuticals Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Phathom Pharmaceuticals Inc. is PHAT:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Phathom Pharmaceuticals Inc. has its primary listing on NASDAQ. You can trade Phathom Pharmaceuticals Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Phathom Pharmaceuticals Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Phathom Pharmaceuticals Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Phathom Pharmaceuticals Inc..